← Leaderboards
Heidi M. Mansour
University Of Arizona
$4,596,984
Attributed
$12,279,520
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,279,520 · 7
By mechanism
U01$8,020,322 · 1
R01$2,736,990 · 1
R21$1,021,990 · 3
P01$500,218 · 2
Top collaborators
- Meredith Hay10 shared
- John P Konhilas10 shared
- Stephen M Black4 shared
- Jeffrey R Fineman4 shared
- Louise Hecker2 shared
- Julie Gunnells Ledford2 shared
- Yuanpu Peter Di1 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Victor J Hruby$15,253,987
- Todd W Vanderah$11,756,178
- Penny A Dacks$79,872
- John P Konhilas$2,673,441
- Frank Porreca$26,550,739
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposIn VivoClinical TrialsIn VitroFormulationGenerationsSafetyLeadPharmaceutical PreparationsToxicologyClinical DevelopmentPeptidesProductionProgramsDocumentationMedicalToxic EffectDrug FormulationsDoseVascular DiseasesMouse ModelInflammatoryEndotheliumDementia
Grant awards (24)
Optimization of a novel antimicrobial for pulmonary delivery to fight respiratory infections$184,375
R21 · FY2025 · AI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,535,000
U01 · FY2023 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$679,894
U01 · FY2023 · AG
Core D: Drug Development$109,264
P01 · FY2023 · CA · contact PI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,145,632
U01 · FY2022 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$766,972
U01 · FY2022 · AG
Core D: Drug Development$104,734
P01 · FY2022 · CA · contact PI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$48,092
U01 · FY2022 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,596,374
U01 · FY2021 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$380,202
U01 · FY2021 · AG
Core D: Drug Development$107,161
P01 · FY2021 · CA · contact PI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$16,031
U01 · FY2021 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,506,750
U01 · FY2020 · AG
Perinatal NO signaling in congenital heart disease$682,425
R01 · FY2020 · HL · contact PI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$345,375
U01 · FY2020 · AG
Core D: Drug Development$90,462
P01 · FY2020 · CA · contact PI
Perinatal NO signaling in congenital heart disease$682,425
R01 · FY2019 · HL
Surfactant Protein A as a Novel Therapeutic for Asthma$230,250
R21 · FY2019 · AI
Core D: Drug Development$88,597
P01 · FY2019 · CA · contact PI
Perinatal NO signaling in congenital heart disease$682,425
R01 · FY2018 · HL
Preclinical development of a novel Nrf2-activator formulation for the treatment of idiopathic pulmonary fibrosis$226,805
R21 · FY2018 · AG
Surfactant Protein A as a Novel Therapeutic for Asthma$191,875
R21 · FY2018 · AI
Perinatal NO signaling in congenital heart disease$689,715
R01 · FY2017 · HL
Preclinical development of a novel Nrf2-activator formulation for the treatment of idiopathic pulmonary fibrosis$188,685
R21 · FY2017 · AG